181 related articles for article (PubMed ID: 6530890)
21. Benzbromarone as a long-term uricosuric agent.
Bluestone R; Klinenberg J; Lee IK
Adv Exp Med Biol; 1980; 122A():283-6. PubMed ID: 6999849
[No Abstract] [Full Text] [Related]
22. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
Mertz DP
Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
[No Abstract] [Full Text] [Related]
23. [The effect of benzbromaron in gout patients with limited kidney function].
Kuzmits R; Bresnik W; Müller MM
Fortschr Med; 1979 Nov; 97(44):2057-61. PubMed ID: 511087
[TBL] [Abstract][Full Text] [Related]
24. [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].
Zöllner N; Griebsch A; Fink JK
Dtsch Med Wochenschr; 1970 Nov; 95(48):2405-12. PubMed ID: 5480261
[No Abstract] [Full Text] [Related]
25. [The effect on uric acid and other laboratory parameters. A long-term study].
Dorn M
ZFA (Stuttgart); 1982 Feb; 58(5):296-300. PubMed ID: 7043937
[No Abstract] [Full Text] [Related]
26. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
Fortschr Med; 1979 May; 97(17):835-6. PubMed ID: 437646
[No Abstract] [Full Text] [Related]
27. Simultaneous determination of allopurinol, oxipurinol and uric acid in human plasma by high-performance liquid chromatography.
Nissen P
J Chromatogr; 1982 Mar; 228():382-6. PubMed ID: 7076766
[No Abstract] [Full Text] [Related]
28. Clinical evaluation of benzbromarone: a new uricosuric drug.
Sorensen LB; Levinson DJ
Arthritis Rheum; 1976; 19(2):183-90. PubMed ID: 1259799
[TBL] [Abstract][Full Text] [Related]
29. [Effect of an allopurinol/benzbromaron preparation on the composition of urine in a circadian course].
Hesse A; Schneeberger W; Vahlensieck W
Klin Wochenschr; 1987 Mar; 65(5):218-24. PubMed ID: 3573681
[TBL] [Abstract][Full Text] [Related]
30. Excellent response to the clinical treatment of tophaceous gout.
Caldas CA; Fuller R
Clin Rheumatol; 2007 Sep; 26(9):1553-5. PubMed ID: 17047891
[TBL] [Abstract][Full Text] [Related]
31. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
32. Oxypurinol nephrolithiasis in regional enteritis secondary to allopurinol therapy.
Stote RM; Smith LH; Dubb JW; Moyer TP; Alexander F; Roth JL
Ann Intern Med; 1980 Mar; 92(3):384-5. PubMed ID: 7356232
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
34. Benzbromarone therapy in management of refractory gout.
Kumar S; Ng J; Gow P
N Z Med J; 2005 Jun; 118(1217):U1528. PubMed ID: 15980902
[TBL] [Abstract][Full Text] [Related]
35. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
36. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.
Heel RC; Brogden RN; Speight TM; Avery GS
Drugs; 1977 Nov; 14(5):349-66. PubMed ID: 338280
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Breithaupt B; Tittel M
Eur J Clin Pharmacol; 1982; 22(1):77-84. PubMed ID: 7094977
[TBL] [Abstract][Full Text] [Related]
38. [Serum uric acid and uric acid elimination after benzbromarone therapy in patients with gout and hyperuricemia].
Matzkies F; Neuwirth R; Berg G
Fortschr Med; 1976 Sep; 94(26):1427-9. PubMed ID: 976920
[TBL] [Abstract][Full Text] [Related]
39. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
[TBL] [Abstract][Full Text] [Related]
40. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
